- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02281292
A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
A Randomized, Sham Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Diabetic Macular Edema
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This first-in-human study will be conducted in 2 parts. Part 1 is an ascending dose design to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of various single IVT doses of LKA651 in up to 48 subjects with diabetic macular edema. Subjects will be randomized to receive active or sham injections in a 3:1 ratio. A total of 6 cohorts (8 subjects per cohort) may be enrolled in Part 1. Each subject will participate in a screening/eligibility period (up to 60 days), a treatment period (single day), and an 84 day follow up period. A total of up to 11 visits will take place, all on an out-patient basis. An independent data monitoring committee (DMC) will be chartered to review cumulative safety data and approve each dose escalation and cohort progression in this first-in-human trial.
Part 2 is a double-masked design to assess the safety/tolerability, pharmacokinetics and pharmacodynamics of a single IVT dose of LKA651 when co-administered with Lucentis®. A total of up to 3 cohorts (8 subjects per cohort) may be enrolled in Part 2. Each subject will participate in a screening/eligibility period (up to 60 days), a treatment period (combination therapy, single day), and an 84 day follow up period. A total of up to 11 visits will take place, all on an out-patient basis. For the LKA651 vs sham injections, the unmasked ophthalmologist is not permitted to do any of the assessments except for the injection (and an inspection of the injection site immediately following). All other ocular assessments after randomization will be conducted by a second ophthalmologist masked to the type of injection (active or sham). The Lucentis injection (Part 2) is given open label to all patients following either the LKA651 or sham injection.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained.
- Type 1 or type 2 diabetes that is actively managed by a physician and hemoglobin A1C ≤ 12% at screening/eligibility.
- Negative pregnancy test results at screening/eligibility and pre-injection on treatment day.
- Diabetic macular edema (DME) with center involvement in at least one eye, including those with focal or diffuse DME.
- ETDRS letter score in the study eye of 55 letters or worse (approximate Snellen equivalent of 20/80). The non-study eye (fellow eye) should be ≥ 60 letters or better (approximate Snellen equivalent of 20/63) at Day 1 pre-dose.
- Safe to withhold treatment of the study eye with laser photocoagulation, intravitreal steroid injection, or intravitreal vascular endothelial growth factor (VEGF) inhibitor (Part 1) for the duration of the study.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Proliferative diabetic retinopathy in the study eye, with the exception of tufts of neovascularization less than 1 disc area with no vitreous hemorrhage.
- Any progressive disease of the retina (e.g. uveitis, rod-cone dystrophy) or optic nerve (e.g. glaucoma) other than diabetic retinopathy.
- Any active infection involving ocular adnexa including infectious conjunctivitis, keratitis, scleritis, endophthalmitis, as well as idiopathic or autoimmune-associated uveitis in either eye.
- Ocular disorders in the study eye that may confound interpretation of study results, including retinal vascular occlusion, retinal detachment, macular hole, or choroidal neovascularization of any cause (e.g., AMD, ocular histoplasmosis, or pathologic myopia).
- Cataract surgery in the study eye, Yttrium-Aluminum-Garnet (YAG) laser capsulotomy or any intraocular surgery within the past 6 months preceding Day 1.
- Use of systemic anticoagulant therapy during the study, e.g., warfarin, heparin, etc. The use of aspirin is not an exclusion.
- Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, whichever is longer; or longer if required by local regulations.
- Pregnant or nursing (lactating) women.
- Women of child-bearing potential, unless using highly effective methods of contraception during dosing of study treatment.
- Other protocol-defined exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LKA651 (Part 1)
LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
|
|
Placebo Comparator: Sham injection (Part 1)
Sham injection in the study eye
|
Mock injection administered as an empty hub without needle
|
Experimental: LKA651 and Lucentis (Part 2)
LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
|
Other Names:
|
Placebo Comparator: Sham injection and Lucentis (Part 2)
Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
|
Mock injection administered as an empty hub without needle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with a serious adverse event (SAE) that, in the opinion of the investigator, is related to the study drug
Time Frame: Up to Day 85
|
Up to Day 85
|
Number of subjects experiencing a non-serious adverse event
Time Frame: Up to Day 85
|
Up to Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass x time / volume] (AUC(0-tlast))
Time Frame: Up to Day 85
|
Contingent upon observed serum concentration levels
|
Up to Day 85
|
The area under the serum concentration-time curve from time zero to time 't' where t is a defined time point after administration [mass x time / volume] (AUC (0-t))
Time Frame: Up to Day 85
|
Contingent upon observed serum concentration levels
|
Up to Day 85
|
The observed maximum serum concentration following drug administration [mass / volume] (Cmax)
Time Frame: Up to Day 85
|
Contingent upon observed serum concentration levels
|
Up to Day 85
|
The time to reach the maximum serum concentration after drug administration [time] (Tmax)
Time Frame: Up to Day 85
|
Contingent upon observed serum concentration levels
|
Up to Day 85
|
The dose normalized observed maximum serum concentration following drug administration [mass*dose / volume] (Cmax/D)
Time Frame: Up to Day 85
|
Contingent upon observed serum concentration levels
|
Up to Day 85
|
The dose-normalized area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [mass*dose x time / volume] (AUC/D)
Time Frame: Up to Day 85
|
Up to Day 85
|
|
Central subfield thickness
Time Frame: Up to Day 85
|
Contingent upon observed serum concentration levels
|
Up to Day 85
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Sr. Clinical Scientist, CSI, ID/Ophtha, Alcon Research
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LKA651X-2101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Macular Edema
-
OcugenNot yet recruitingDiabetic Macular Edema | Center Involved Diabetic Macular Edema
-
California Retina ConsultantsRegeneron PharmaceuticalsCompletedDiabetic Macular Edema | Cystoid Macular EdemaUnited States
-
OculisICON plcRecruitingDiabetic Macular EdemaUnited States
-
Novartis PharmaceuticalsNot yet recruiting
-
Vista KlinikNot yet recruitingDiabetic Macular Edema
-
Chinese University of Hong KongRecruiting
-
Laboratorios Sophia S.A de C.V.RecruitingDiabetic Macular EdemaColombia, Mexico
-
Centre Hospitalier Universitaire DijonRecruiting
-
Uptown Eye SpecialistsNot yet recruitingDiabetic Macular Edema
-
Hospices Civils de LyonRecruiting
Clinical Trials on LKA651 ophthalmic solution
-
Novartis PharmaceuticalsCompletedDiabetic Macular Edema | Macular Edema | Neovascular Age-related Macular Degeneration | Retinal Vein OcclusionsPuerto Rico, United States
-
Laboratorios Sophia S.A de C.V.WithdrawnConjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic ConjunctivitisMexico
-
Alcon ResearchCompletedOcular Hypertension | Open-angle Glaucoma
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States
-
Aldeyra Therapeutics, Inc.Completed
-
Santen Pharmaceutical Co., Ltd.CompletedPrimary Open Angle Glaucoma | Ocular HypertensionJapan
-
Aldeyra Therapeutics, Inc.Completed
-
Mimetogen Pharmaceuticals USA, Inc.CompletedDry Eye SyndromesUnited States
-
Aldeyra Therapeutics, Inc.CompletedAllergic ConjunctivitisUnited States